A Phase 1 interventional study of placebo and Baricitinib tablets in Healthy, Active Non-segmental Vitiligo and Severe Alopecia Areata, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Alopecia Areata with a site in China — 9 open to participants now, 13 under way, 6 of them phase 3. Alopecia Areata · China.
Among the 24 studies in Alopecia Areata with a site in China, this one is the 12th largest by planned enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2026, is one of 2 in phase 1, reaches primary completion later than 5 of the 12 other live ones, and was the 21st registered.
222 studies on the registry are indexed under Alopecia Areata; 63 are open to participants now.
Browse Alopecia Areata studies →9 of the 24 studies in Alopecia Areata with a site in China are open now. Recruiting first, the newest first:
Jiangsu vcare pharmaceutical technology co., LTD · Sites in China
Ages 12–18
Jiangsu vcare pharmaceutical technology co., LTD · Sites in China
Ages 18–65
Pfizer · Sites in China, United States, Canada and 2 more countries
Ages 12+
Eli Lilly and Company · Sites in China, United States, Canada and 4 more countries
Ages 18–60
Pfizer · Sites in China, United States, Czechia and 6 more countries
Ages 6–14
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Alopecia Areata studies recruiting now, 17 (40%) set no upper age limit and 22 (51%) stop at 75 or younger; 20 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 11
First in 2012; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 50 across 172 interventional studies indexed under Alopecia Areata.
Median enrollment 163 across the 22 interventional studies, 300 across the 2 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Innovent Biologics, Inc. has 1 study filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
3 of the studies in Alopecia Areata with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT06573593Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEfficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study | 2026-12-31 |
| NCT07533006Eli Lilly and CompanyA Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Alopecia Areata with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and severe alopecia areata trial participants. The study is divided into 2 parts, with Part 1 involving healthy trial participants lasting up to 24 weeks, and Part 2 involving active non-segmental vitiligo trial participants and severe alopecia areata trial participants lasting up to 48 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
oral, 2mg, once daily
Drug: Baricitinib tablets
subcutaneous injection/intravenous infusion,single or multiple dosing
Drug: placebo
subcutaneous injection/intravenous infusion,single or multiple dosing
Drug: IBI3013
placebo
Baricitinib tablets
Recombinant anti-Interleukin-15 (IL-15) monoclonal antibody injection
Part 1: Number of participants with at least one treatment-emergent adverse event
Time frame: up to 24 weeks
Part 1: Number of participants with at least one Serious treatment-emergent adverse event
Time frame: up to 24 weeks
Part 2: Number of participants with at least one treatment-emergent adverse event
Time frame: up to 48 weeks
Part 2: Number of participants with at least one Serious treatment-emergent adverse event
Time frame: up to 48 weeks
Part 1: Cmax following a single dose of IBI3013.
Time frame: up to 24 weeks
Part 1: Tmax following a single dose of IBI3013.
Time frame: up to 24 weeks
Part 1: AUC following a single dose of IBI3013.
Time frame: up to 24 weeks
Part 1: Cmin following a single dose of IBI3013.
Time frame: up to 24 weeks
Part 1: CL/F or CL following a single dose of IBI3013.
Time frame: up to 24 weeks
Part 1: Vd/F or Vd following a single dose of IBI3013.
Time frame: up to 24 weeks
Part 1: T1/2 following a single dose of IBI3013.
Time frame: up to 24 weeks
Part 1: Positive rate of anti-drug antibody following a single dose of IBI3013.
Time frame: up to Day85
Part 2: Cmax following multiple doses of IBI3013.
Time frame: up to 48 weeks
Part 2: Tmax following multiple doses of IBI3013.
Time frame: up to 48 weeks
Part 2: AUC following multiple doses of IBI3013.
Time frame: up to 48 weeks
Part 2: Cmin following multiple doses of IBI3013.
Time frame: up to 48 weeks
Part 2: CL/F following multiple doses of IBI3013.
Time frame: up to 48 weeks
Part 2: Vd/F following multiple doses of IBI3013.
Time frame: up to 48 weeks
Part 2: T1/2 following multiple doses of IBI3013.
Time frame: up to 48 weeks
Part 2: Positive rate of anti-drug antibody following multiple doses of IBI3013.
Time frame: up to 28 weeks
Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innovent Biologics (Suzhou) Co. Ltd. →